

PE-Labeled Monoclonal Anti-Human CD197 / CCR7 Antibody, Mouse IgG2a (AS651) (0.03% Proclin)

Catalog # FABm057-01



Source

Monoclonal Anti-Human CD197 / CCR7 Antibody, Mouse IgG2a (AS651) is a recombinant mouse monoclonal antibody expressed in HEK293 cells, providing improved batch-to-batch consistency and long-term supply security.

Clone

AS651

Isotype

Mouse IgG2a, Kappa

Host Species

Mouse

Reactivity

Human

Immunogen

Purified Human CD197 / CCR7 Protein

Conjugate

PE

Excitation Wavelength: 488 nm / 561 nm

Emission Wavelength: 575 nm

Specificity

This antibody specifically recognizes human CD197 / CCR7 protein.

Application

Flow Cytometry (Evaluation of the expression of CD197 / CCR7 on Human cells).

Recommended Dilution

1:20

Isotype Control

The isotype control is sold separately; please refer to Cat. No. [DNP-PM487](#) for product information.

Form

Liquid

Formulation

Supplied as 0.2 µm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.

Please contact us for customized product forms or formulations.

Shipping

Liquid product is shipped at blue ice.

Storage

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- Store at 2-8 °C for 12 months.


Notices

Product Specific Notices: For research use only.

ACRO Quality Management System

- [QMS\(ISO, GMP\)](#).
- [Quality Advantages](#)

Bioactivity-FACS



Flow cytometric analysis of CCR7-HEK293T cells stained with PE-Labeled Monoclonal Anti-Human CD197 / CCR7 Antibody, Mouse IgG2a (AS651) (Cat. No. FABm057-01) at a 1:20 dilution. For the recommended staining condition, 5 µL of antibody stock solution is used to stain 1e6 cells in a final volume of 100 µL. An isotype control antibody was used as a negative control. PE fluorescence signal was measured to evaluate the binding activity of the antibody (QC tested).

Background

The anti-Human CD197 (CCR7) monoclonal antibody specifically binds to cell-surface CCR7 (CD197), a seven-transmembrane G-protein-coupled receptor that interacts with chemokines CCL19 and CCL21. CCR7 mediates leukocyte homing to secondary lymphoid tissues, and its differential expression distinguishes T cell subsets. Aberrant CCR7 expression is linked to lymphoma metastasis and autoimmune disease progression, making it a key target for immunotherapy research. PE-labeled CCR7 antibody can facilitate relevant drug research and development.



www.acrobiosystems.com